Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Bayer discloses HIV protease inhibitors

Aug. 16, 1996

VX-478 covered under U.S. patent for HIV/AIDS

Aug. 9, 1996

RD4-2025: Selective HIV-1 reverse transcriptase inhibitor in vitro

Aug. 9, 1996

GalaGen's Sporidin G enters phase II/III

Aug. 9, 1996

Immtech's r(m)CRP HIV treatment covered under U.S. patent

Aug. 9, 1996

Cel-Sci now holds full rights to HGP-30

Aug. 9, 1996

BioChem Pharma to challenge Epivir patent

Aug. 9, 1996

A-76202: Alpha-glucosidase/sucrase-isomaltase complex inhibitor from Sankyo

Aug. 9, 1996

Emory University files Epivir patent infringement action

Aug. 9, 1996

Study of Epivir's effect on HIV survival and disease progression terminated

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.